Clinical trial · Observational
BE.Amycon Biobank & Data Registry UZ Leuven
BE.Amycon Biobank & Data Registry UZ Leuven: Human Body Material (HBM) Collection and Data Collection of Patients With Amyloidosis
NCT07172243CI-TRIAL-00104130recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260926-000001
Summary
Brief summary (as posted)
The goal of this study is to collect and store human body material (HBM) of patients with amyloidosis in a biobank "BE.Amycon biobank" for future research and to collect clinical data of patients with amyloidosis in a database "BE.Amycon data registry".
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| AL Amyloidosis | AL Amyloidosis | ONTOLOGY_EXACT | 0.98 |
| Amyloidosis | Amyloidosis | ONTOLOGY_EXACT | 0.98 |
| Amyloidosis Cardiac | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Establishment of a data registry: participant baseline demographics
- timeFrame
- Baseline
- description
- Demographic characteristics of amyloidosis participants will be assessed at baseline.
- measure
- Establishment of a data registry: description of the disease characteristics of patients with amyloidosis at diagnosis
- timeFrame
- Baseline
- description
- Disease characteristics of amyloidosis (disease presentation and symptoms, type of organ involvment, results of diagnostic tests (lab values, imaging, biopsy)) will be collected at moment of diagnosis.
- measure
- Establishment of a data registry: treatment in participants with amyloidosis
- timeFrame
- From enrollment of the patient until death, until loss to follow-up or withdrawal of informed consent, whichever comes first, up to 10 years
- description
- Description of treatment (type of treatment per line of treatment) of participants with amyloidosis within routine clinical care.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Provide consent and sign informed consent form * Age 18 years or older * Diagnosis of amyloidosis (suspected or confirmed, any subtypes) * For the prospective sample collection only: newly diagnosed (any subtype) or at relapse (AL amyloidosis) Exclusion Criteria: * Not willing to sign informed consent * Not able to sign informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.